Physician

Heidi A Berdin, MD

According to 2025 Medicare claims, Heidi Berdin, MD (NPI: 1659368751) practices internal medicine in the Lake Havasu City-Kingman, AZ market, with the plurality of this provider's patient population coming from Mohave, AZ. This provider's primary affiliated billing organization is HAVASU LUNG AND SLEEP DISORDERS CENTER LLC (NPI: 1841527645; TIN: 271312908) and primary practice location at 86403-5885.

Berdin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,048 traditional Medicare patients, billed 4,229 HCPCS/CPT codes, and received $296,869 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 5,024 prescription claims across 766 beneficiaries totaling $2,873,331 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 7,172 claims. Open Payments data shows 77 records totaling $2,629. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,194,060 to $2,873,331. For DME billing, reported payments did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,198	6,291	$493,544
2016	1,110	6,644	$461,679
2017	1,034	5,935	$392,592
2018	1,084	5,558	$384,229
2019	1,130	5,828	$423,724
2020	1,058	4,901	$356,062
2021	1,056	4,841	$421,334
2022	1,117	5,334	$421,187
2023	1,113	5,106	$376,642
2024	1,048	4,229	$296,869

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	553	3,572	$1,194,060
2016	588	4,042	$1,276,203
2017	568	4,103	$1,262,316
2018	580	4,038	$1,276,329
2019	619	4,237	$1,770,638
2020	626	4,131	$2,139,843
2021	638	4,185	$2,073,621
2022	733	4,684	$2,365,035
2023	741	4,864	$3,197,553
2024	766	5,024	$2,873,331

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	1,993	8,355	$832,487
2016	1,878	7,813	$588,903
2017	1,865	8,317	$506,810
2018	1,952	7,723	$442,463
2019	2,317	8,950	$656,201
2020	2,421	9,550	$965,277
2021	2,097	9,014	$994,797
2022	2,059	8,134	$892,546
2023	2,082	8,253	$906,721
2024	1,942	7,172	$718,390

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	449	714	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	771	1,399	$90
94729	Test to examine how well the lungs exchange gases	236	240	$40
94726	Test to determine lung volumes using sensors	235	240	$38
94060	Test to measure expiratory airflow and volume changes before and after medication administration	236	241	$26

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	663	30,720	$633,951
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	665	31,080	$629,781
Uptravi	Selexipag	13	360	$281,389
Adempas	Riociguat	17	450	$212,696
Zemaira	Alpha-1-Proteinase Inhibitor	13	343	$169,426

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	53	363	$277,867
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	11	104	$105,704
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	111	905	$69,888
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	62	381	$58,543
J7699	Noc drugs, inhalation solution administered through dme	N	N/R	14	$38,693

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	77	$2,629	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Heidi A. Berdin, MD?

Tedicare shows public-source Medicare data for Heidi A. Berdin, MD (NPI 1659368751), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Heidi A. Berdin, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Heidi A. Berdin, MD?

Heidi A. Berdin, MD is linked to HAVASU LUNG AND SLEEP DISORDERS CENTER LLC (billing NPI 1841527645) in the available physician profile data.

Does Heidi A. Berdin, MD have Open Payments data?

Heidi A. Berdin, MD has 77 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.